Structured page family:Cost guide

Vosoritide Cost Guide: Insurance, Cash Pay, and Savings

In the United States, Vosoritide costs depend on brand, pharmacy, insurance design, and whether the patient qualifies for manufacturer savings programs.

Active Market
This page is designed for US treatment decisions and uses US-first pricing and savings sources.
Official pricing
Verify current pricing directly on official Voxzogo pages before starting, because list pricing, self-pay offers, and eligibility terms can change.
Cash-pay reality
Official cash-pay pricing varies by pharmacy and dose. Contact multiple pharmacies or use a prescription discount service for current rates.
Insurance coverage
Commercial coverage for Vosoritide varies by plan and indication. Prior authorization is commonly required.
Savings and coupons
Manufacturer savings programs may reduce out-of-pocket cost for eligible commercially insured patients.
Prior Authorization
Prior authorization is common and may require documentation of diagnosis, prior treatments, and clinical need.

Price Breakdown

List price (monthly)
~$30,000-$40,000/month
Average wholesale price
~$28,000-$38,000/month
Pharmacy acquisition estimate
~$26,000-$35,000/month
Typical negotiated rate
~$22,000-$30,000/month
Price per dose
~$1,000 per daily injection (weight-based)
Annual cost at list price
~$360,000-$480,000

Pharmacy Price Comparison

PharmacyPrice RangeNotes
Specialty pharmacy$30,000-$40,000/monthREMS-required

Insurance Coverage Landscape

Commercial plans
~60-70% with genetic diagnosis
Medicare Part D
Rare; case-by-case
Medicaid
Some states cover with extensive documentation
VA coverage
Case-by-case
TRICARE
Case-by-case
Employer plan typical tier
Tier 5 specialty; max out-of-pocket

Prior Authorization Guide

Required Documentation
  • Genetic confirmation of achondroplasia
  • Open growth plates (bone age)
  • Age 5-14 years
  • Pediatric endocrinologist attestation
Common Denial Reasons
  • No genetic test
  • Closed growth plates
  • Outside approved age range
  • Not prescribed by pediatric endocrinologist
Appeal Template Points
  • FDA-approved for achondroplasia
  • Genetic test attached
  • Open growth plates confirmed
  • No alternative therapy
  • First-ever treatment for this condition
Expected timeline: 2-4 weeks

Savings Programs and Patient Assistance

BioMarin PAP
manufacturer
Eligibility: Uninsured/underinsured
Savings: May provide at reduced or no cost
Income limit: Case-by-case
Enrollment: complex
Extensive application
Copay assistance
copay
Eligibility: Commercially insured
Savings: May reduce to $0
Income limit: None
Enrollment: moderate
Annual cap

Generic and Biosimilar Status

No generic currently available
Expected: No generic expected

Cost by Dose

Dose/RegimenMonthlyAnnual
15 mcg/kg daily$30,000-$40,000$360,000-$480,000

Annual Cost Projection

Year 1
$0-$480,000
Year 2
$0-$480,000
Year 3
$0-$480,000
Assumptions
  • Ultra-rare genetic disease
  • Insurance variable

Cost-Saving Strategies

  • 1.Genetic testing and specialist documentation are essential
  • 2.Apply for BioMarin PAP immediately if coverage gaps
  • 3.Work with patient advocate for appeals
  • 4.Explore state rare disease programs

International Price Comparison

CountryPrice RangeNotes
UKNHS specialized commissioningNICE evaluation

Need help comparing vosoritide paths?

Use the provider matcher to package treatment interest, insurance, budget, urgency, and state context before you commit to a prescribing path.

Find a vosoritide provider
Trust Summary
Reviewed 2026-04-27 by PeptideScholar editorial review. This page currently cites 2 official sources.
Pricing, savings eligibility, and coverage rules can change quickly. Verify all current figures and terms directly on official brand pages before acting.

Vosoritide Cost FAQ

Sources

  1. 1. C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia.
    N Engl J Med • 2019
    Claim type: clinical
    View source →
  2. 2. FDA Information on Vosoritide
    FDA • 2026
    Claim type: regulatory
    View source →

This content is for informational purposes only and does not constitute medical advice.